anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-19 and is reviewed periodically as new material appears.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Hart (1874–1953), American biochemist at the University of Wisconsin-Madison who studied farm animal diet. Brian S. Hartley FRS (1926–2021). British biochemist at Imperial College London. Known for studies on chymotrypsin and other proteolytic enzymes. Hamilton Hartridge FRS (1886–1976). British eye physiologist known in biochemistry for the continuous-flow method for following fast reactions. Demis Hassabis (b. 1976). British computer scientist and artificial intelligence researcher at University College London. Nobel Prize in chemistry 2024. Reinhart Heinrich (1946–2006). German biophysicist at the Humboldt University of Berlin, noted for the origin and development of metabolic control analysis. Max Henius (1859–1935). Danish-American biochemist who specialized in fermentation processes. Founder of the Chicago-based American Brewing Academy. Victor Henri (1872–1940). French physical chemist of Russian parents at the University of Liège. He was the first to apply ideas of physical chemistry to the properties of enzymes. Avram Hershko (b. 1937 as Herskó Ferenc). Hungarian-Israeli biochemist at the Technion (Haifa), known for the discovery of ubiquitin-mediated protein degradation. Nobel Prize in Chemistry (2004). Foreign associate Natl. Acad. Sci. USA.
A board foot is a United States and Canadian unit of approximate volume, used for lumber. It is equivalent to 1 inch × 1 foot × 1 foot (144 in3 or 2,360 cm3). It is also found in the unit of density pounds per board foot. In Australia and New Zealand the terms super foot or superficial foot were formerly used for this unit. The exact volume of wood specified is variable and depends on the type of lumber. For planed lumber the dimensions used to calculate board feet are nominal dimensions, which are larger than the actual size of the planed boards. See Dimensional lumber for more information on this.
=== Industrial sources === PFOA is released directly from industrial sites. For example, the estimate for the DuPont Washington Works facility is a total PFOA emissions of 80,000 pounds (lbs) in 2000 and 1,700 pounds in 2004. A 2006 study, with two of four authors being DuPont employees, estimated about 80% of historical perfluorocarboxylate emissions were released to the environment from fluoropolymer manufacture and use. PFOA can be measured in water from industrial sites other than fluorochemical plants. PFOA has also been detected in emissions from the carpet industry, paper and electronics industries. The most important emission sources are carpet and textile protection products, as well as fire-fighting foams.
In the above examples, neither whole rice nor canned chickpeas have sufficient amounts of all required amino acids when used as the only source of 46.2 g of daily protein. The insufficient amino acid is called the limiting amino acid: lysine in rice and methionine in chickpeas. Consuming only chickpeas or other plant-based foods that also lack methionine for long periods of time will result in deficiency of the amino acid, and severe health problems will arise.
Sources: en.wikipedia.org
Player Luke Davis gave evidence that he was instructed to keep the injections secret from Reid and other coaching staff, although other players disputed that they received such instructions. In May 2012, in a meeting of club administrators including Reid and Dank, Dank was directed to cease giving injections to players; however, evidence given by players indicated that the program was reduced rather than ceased, with many continuing to receive injections until as late as July. Evidence showed that Dank continued to liaise with sports scientists and pharmacists to seek new supplements into August; investigations later described the program as being often experimental in nature. Dank was dismissed from the club in September 2012 because he had made unauthorised expenditures, the exact nature of which was not made public. Essendon's on-field performances during the 2012 season began strongly and finished weakly, a coincidence which was later scrutinised in the context of the program. At the end of May, when the program began to be rewound, the club sat second on the ladder with an 8–1 record. The club then began to lose many players to soft tissue injuries; it won three of its next six games during the middle part of the year to drop to sixth; then lost its last seven games to finish eleventh with an 11–11 record. The CAS acknowledged these observations in its findings, noting that they carried no weight as evidence but describing them as "at least not inconsistent" with the timeline of the program.
Indigenous healers often claim to have learned by observing that sick animals change their food preferences to nibble at bitter herbs they would normally reject. Field biologists have provided corroborating evidence based on observation of diverse species, such as chickens, sheep, butterflies, and chimpanzees. The habit of changing diet has been shown to be a physical means of purging intestinal parasites. Sick animals tend to forage plants rich in secondary metabolites, such as tannins and alkaloids.
== Nomenclature == This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH2 group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-alanine:NAD+ oxidoreductase (deaminating). Other names in common use include AlaDH, L-alanine dehydrogenase, NAD+-linked alanine dehydrogenase, alpha-alanine dehydrogenase, NAD+-dependent alanine dehydrogenase, alanine oxidoreductase, and NADH-dependent alanine dehydrogenase. T
Sources: en.wikipedia.org
He created the library's first Young Readers Center in the Jefferson Building in 2009, and the first large-scale summer intern (Junior Fellows) program for university students in 1991. Under Billington, the library sponsored the Gateway to Knowledge in 2010 to 2011, a mobile exhibition to ninety sites, covering all states east of the Mississippi, in a specially designed eighteen-wheel truck. This increased public access to library collections off-site, particularly for rural populations, and helped raise awareness of what was also available online. Billington raised more than half a billion dollars of private support to supplement Congressional appropriations for library collections, programs, and digital outreach. These private funds helped the library to continue its growth and outreach in the face of a 30% decrease in staffing, caused mainly by legislative appropriations cutbacks. He created the library's first development office for private fundraising in 1987. In 1990, he established the James Madison Council, the library's first national private sector donor-support group. In 1987, Billington also asked the Government Accountability Office (GAO) to conduct the first library-wide audit. He created the first Office of the Inspector General at the library to provide regular, independent reviews of library operations. This precedent has resulted in regular annual financial audits at the library; it has received unmodified ("clean") opinions from 1995 onward.
This process is referred to as acclimatization: the maximum rate of sweating increases and its solute composition decreases. The volume of water lost in sweat daily is highly variable, ranging from 100 to 8,000 millilitres per day (0.041 to 3.259 imp fl oz/ks). The solute loss can be as much as 350 mmol/d (or 90 mmol/d acclimatised) of sodium under the most extreme conditions. During average intensity exercise, sweat losses can average up to 2 litres (0.44 imp gal; 0.53 US gal) of water/hour. In a cool climate and in the absence of exercise, sodium loss can be very low (less than 5 mmol/d). Sodium concentration in sweat is 30–65 mmol/L, depending on the degree of acclimatisation. Horses have a thick, waterproofed, hairy coat that would normally block the rapid translocation of sweat water from the skin to the surface of the hair required for evaporative cooling. To solve this, horses have evolved a detergent-like protein, latherin, that they release at high concentrations in their sweat. Their perspiration unlike humans is created by apocrine glands. This protein, by wetting the horses' coat hairs facilitate water flow for cooling evaporation. The presence of this protein can be seen in the lathering that often occurs on the coats of sweating horses, especially when rubbed. In hot conditions, horses during three hours of moderate-intensity exercise can lose 30 to 35 litres (6.6 to 7.7 imp gal; 7.9 to 9.2 US gal) of water and 100 grams (3.5 oz) of sodium, 198 grams (7.0 oz) of chloride and 45 grams (1.6 oz) of potassium.
=== Mechanics of spitting === Spitting cobras of the genera Naja and Hemachatus, when irritated or threatened, may eject streams or a spray of venom a distance of 1.2 metres (4 ft) to 2.4 metres (8 ft). These snakes' fangs have been modified for the purposes of spitting; inside the fangs, the channel makes a 90° bend to the lower front of the fang. Spitters may spit repeatedly and still be able to deliver a fatal bite. Spitting is a defensive reaction only. The snakes tend to aim for the eyes of a perceived threat. A direct hit can cause temporary shock and blindness through severe inflammation of the cornea and conjunctiva. Although usually no serious symptoms result if the venom is washed away immediately with plenty of water, blindness can become permanent if left untreated. Brief contact with the skin is not immediately dangerous, but open wounds may be vectors for envenomation.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.